SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2102Results from Reverset Study 203 Accepted for Late Breaker Presentations at 3rd Iquidditch-7/7/2005
2101You're right, badly phrased on my part. Substitute "value" for &qtuck-7/5/2005
2100<b> I have no idea if it is adding or subtracting cash flow to INCY at thimicrocapfun-7/4/2005
2099Listened to the Goldman Sachs presentation made recently by CEO Friedman. Defintuck-6/29/2005
2098DiaDexus seems to be chugging right along. I have no idea if it is adding or sutuck-6/29/2005
2097Surfing on previous post which included mention of Merck's CCR2 program. Hetuck-5/30/2005
2096Q1 2005 Incyte Corporation Earnings Conference Call - Final Fair Disclosure Wmicrocapfun-5/30/2005
2095MTX is front line SoC for RA. Trials in combination with mtx, as it is not conskeokalani'nui-5/5/2005
2094Wilder, Thanks for your kind words. <I> Ccr2 antagonist 3284 - - recentlsoftware salesperson-5/5/2005
2093Sales, I have never seen more accurate CC summaries than your posts. I have ankeokalani'nui-5/5/2005
2092Excellent writeup, thank you sales. INCY is a little like watching paint dry, buquidditch-5/4/2005
20915/4/05 cc notes 1. 1st q results R - - final data in july for P2 trial; anticisoftware salesperson-5/4/2005
2090Listening to the cc with only a part of one ear, but this is a cc worth taking iquidditch-5/4/2005
2089Incyte Announces First Quarter 2005 Results Wednesday May 4, 7:00 am ET Progresnigel bates-5/4/2005
2088[CCR2 and CNS pathology?] Just parking. >>FASEB J. 2005 May;19(7):761-72tuck-4/29/2005
2087Sheddase P1 started.<i> April 6, 2005--Incyte Corporation (Nasdaq:INCY - keokalani'nui-4/6/2005
2086Don't know either, but that is interesting.keokalani'nui-3/23/2005
2085[Downregulation of monocyte CCR2 prevents migration to arterial wall] >>Ctuck-3/23/2005
2084Incyte Up 6%; Morgan Stanley Sees Promising HIV Drug DOW JONES NEWSWIRES March 1Jim Oravetz-3/11/2005
2083Thanks for the clarification Wilder. Jasontnsaf-3/10/2005
2082>>I hope Friedman isn't another wink-wink-good-results-are-coming guy.keokalani'nui-3/10/2005
2081Hi Wilder, The statement <<Friedman was concerned about discussing anythtnsaf-3/10/2005
2080tuck, Friedman was concerned about discussing anything more than the bare boneskeokalani'nui-3/9/2005
2079<i> (iv) can R cover K65r patients? - - haven’t seen too many patients witmicrocapfun-3/8/2005
2078<i> "Based on the viral load reductions seen in patients receiving Remicrocapfun-3/8/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News